The Department of Veterans Affairs has begun a randomized clinical trial to find out whether semaglutide helps people with alcohol use disorder, and the answer will not arrive for years.
For treatment seekers and the facilities that serve them, the practical value of this announcement is not the drug being tested. It is the reminder that medication is an underused part of alcohol care, and that several options already carry FDA approval.
What the CRAVE Trial Will Measure
The study is called Cessation or Reduction of Alcohol Consumption in Veterans, or CRAVE. It will enroll more than 600 veterans between the ages of 18 and 80 who have moderate or severe alcohol use disorder, across 18 VA medical centers nationwide.
Participants receive weekly injections of either semaglutide or a placebo over 24 weeks, followed by a safety follow-up. Researchers will track changes in drinking, overall health, and quality of life. Recruitment began July 28, 2026.
Sites include Ann Arbor, Michigan; Asheville, North Carolina; Durham, North Carolina; Hines, Illinois; Salt Lake City; Decatur, Georgia; Cleveland; Houston; Minneapolis; Orlando, Florida; Palo Alto, California; Philadelphia; Portland, Oregon; Long Beach, California; Los Angeles; Dallas; Seattle; and Madison, Wisconsin.
The VA reports that more than 400,000 veterans in its system carry an alcohol use disorder diagnosis, and cites estimates that the condition affects close to 11 percent of U.S. adults.
Why Semaglutide Drew Researchers Interest
Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, sold as Ozempic and Wegovy. It is not approved for alcohol use disorder.
Interest in the drug for addiction grew because it may act on brain regions involved in how the body experiences reward. An analysis published in March found that patients taking GLP-1 medications had lower rates of alcohol use disorder and other substance use disorders than comparable patients on other diabetes drugs.
People with existing substance use disorders who took these medications also had fewer emergency visits and hospitalizations. Those findings are observational.
Patients prescribed GLP-1 medications differ from those who are not in ways that are difficult to adjust for statistically, including how consistently they engage with medical care.
An association is not proof that the medication caused the difference, which is the entire reason a randomized placebo-controlled trial is being run.
“By exploring emerging treatment options like the use of a GLP-1 for AUD, we aim to expand the tools available to help Veterans take control of their health and recovery,” VA Secretary Doug Collins said in the announcement.
The department was direct about the interim guidance. It discourages veterans from self-medicating or substituting GLP-1 medications for established alcohol use disorder treatment, and urges anyone considering the drug to speak with a healthcare provider first.
Alcohol Addiction Treatment Options Available Today
Three medications already hold FDA approval for alcohol use disorder. Naltrexone reduces cravings and blunts the rewarding effects of drinking.
Acamprosate helps stabilize brain chemistry after drinking stops. Disulfiram produces an unpleasant physical reaction if alcohol is consumed.
These fall under medication-assisted treatment, which pairs FDA-approved medication with individual counseling and behavioral therapy. Despite a solid evidence base, medication remains absent from many treatment plans, and plenty of people researching alcohol addiction treatment have never had it raised with them.
What This Means for Treatment Seekers
Nothing about the CRAVE trial changes what is available or covered today. Semaglutide cannot be prescribed for alcohol use disorder outside a study, and results are years away.
What it should prompt is a more specific question when comparing treatment programs. Ask whether a facility prescribes and manages medication for alcohol use disorder, or whether it treats medication as optional. That single answer separates programs meaningfully.
Finding the Right Rehab
When evaluating alcohol addiction treatment, useful comparison points include whether the program offers medically supervised withdrawal management, whether medication-assisted treatment is available on site, how co-occurring mental health conditions are handled, and what the facility accepts for payment.
Veterans should confirm VA and TRICARE coverage directly, since network rules differ from commercial plans. Veterans interested in the CRAVE trial can contact their local VA medical center or search for it on ClinicalTrials.gov.
Rehab.com’s directory lists verified treatment centers nationwide with details on levels of care, accreditation and insurance accepted. Call
800-985-8516
( 
Sponsored Helpline )
for more information about your treatment optinos.
